O n Tuesday, BMO Capital Markets reaffirmed their Outperform rating on Beam Therapeutics Inc (NASDAQ:BEAM), with a steady price target of $57.00. Currently trading at $26.57, the stock appears ...

Wedbush reaffirmed their outperform rating on shares of Beam Therapeutics (NASDAQ:BEAM – Free Report) in a research note ...

In a report released yesterday, Luca Issi from RBC Capital maintained a Hold rating on Beam Therapeutics (BEAM – Research Report), with a price target of $26.00. The company’s shares closed ...

Beam Therapeutics (NASDAQ:BEAM – Get Free Report) was upgraded by equities research analysts at Scotiabank from a “sector perform” rating to a “sector outperform” rating in a report released on Monday ...

Beam expects that its cash, cash equivalents and marketable securities as of December 31, 2024, will enable the company to fund its anticipated operating expenses and capital expenditure ...

On Tuesday, BMO Capital Markets reaffirmed their Outperform rating on Beam Therapeutics Inc (NASDAQ:BEAM), with a steady price target of $57.00. Currently trading at $26.57, the stock appears ...